MAPT and early-onset autosomal dominant Alzheimer disease: 18F-FTP (commercial name: Tauvid) was the first widely used tau agent, and in 2020 was granted FDA approval “to estimate the density and distribution of aggregated tau NFTs for adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease” (10,42).